

1 **Oxytocin reduces subjective fear in naturalistic social contexts via enhancing top-down middle**
2 **cingulate-amygdala regulation and brain-wide connectivity**

3
4
5 **Authors**

6 Kun Fu^{1,2}, Shuyue Xu^{3,4}, Zheng Zhang^{1,2}, Dan Liu^{1,2}, Ting Xu^{1,2}, Yuan Zhang^{1,2}, Feng Zhou^{5,6},
7 Xiaodong Zhang^{1,2}, Chunmei Lan^{1,2}, Junjie Wang^{1,2}, Lan Wang^{1,2}, Jingxian He^{1,2}, Keith M
8 Kendrick^{1,2}, Bharat Biswal^{2,7}, Zhen Liang^{3,4*}, Weihua Zhao^{1,2*}, Benjamin Becker^{1,2,8,9,10*}

9
10
11 **Affiliations**

12 ¹The Center of Psychosomatic Medicine, Sichuan Provincial Center for Mental Health, Sichuan
13 Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu,
14 China

15 ²MOE Key Laboratory for Neuroinformation, School of Life Science and Technology, University of
16 Electronic Science and Technology of China, Chengdu, China

17 ³School of Biomedical Engineering, Medical School, Shenzhen University, Shenzhen, China

18 ⁴Guangdong Provincial Key Laboratory of Biomedical Measurements and Ultrasound Imaging,
19 Shenzhen, China

20 ⁵Faculty of Psychology, Southwest University, Chongqing, China

21 ⁶Key Laboratory of Cognition and Personality, Ministry of Education, Chongqing, China

22 ⁷Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, USA

23 ⁸State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong,
24 China

25 ⁹Department of Psychology, The University of Hong Kong, Hong Kong, China

26 ¹⁰ **Lead contact**

27
28 ***Corresponding authors**

29 bbecker@hku.hk (B. Becker, lead contact)

30 janezliang@szu.edu.cn (Z. Liang)

31 zarazhao@uestc.edu.cn (W. Zhao)

32
33
34
35
36 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

37 **Abstract**

38 Accumulating evidence from animal and human studies suggests a fear-regulating potential of
39 the neuropeptide oxytocin (OT), yet the clinical translation into novel interventions for
40 pathological fear requires a behavioral and neurofunctional characterization under close-to-real
41 life conditions. Here, we combined a naturalistic fMRI-design inducing high and immersive fear
42 experience in social and non-social contexts with a preregistered between-subjects randomized
43 double-blind placebo-controlled intranasal OT trial (24 IU, n = 67 healthy men). OT reduced
44 subjective fear in non-social and social contexts with small or moderate effect sizes, respectively.
45 In the social fear contexts, OT enhanced left middle cingulate cortex (IMCC) activation and its
46 functional connectivity with the contralateral amygdala, with both neural indices significantly and
47 inversely associated with subjective fear following OT. On the network level, OT enhanced
48 communication between the dorsal attention network (DAN) with the fronto-parietal (FPN) and
49 the default-mode network (DMN) as well as on the more fine-grained level brain-wide
50 communication. These findings indicate a fear-reducing potential of OT under naturalistic
51 conditions with pronounced effects in social contexts, suggesting a high treatment value in
52 disorders with social context-related excessive fear.
53
54

55 Introduction

56 Fear is an evolutionarily conserved and highly adaptive defensive avoidance response,
57 fundamental to surviving and functioning in everyday life¹⁻⁴. The experience of excessive and
58 overwhelming fear represents a hallmark symptom of anxiety and trauma-related disorders⁵⁻⁷.
59 These highly prevalent psychiatric disorders have become a leading cause of disability and are
60 accompanied by personal suffering as well as an enormous socio-economic burden. The
61 conventional pharmacological interventions targeting the classical neurotransmitter (GABA-ergic,
62 serotonergic) systems⁷⁻⁹ are characterized by moderate response rates and potential negative
63 side effects ranging from dizziness towards addiction. While several promising candidate
64 compounds have shown effects in animal models, no new pharmacological treatment for fear or
65 anxiety has entered the clinical practice during the last decades (for recent non-pharmacological
66 developments see e.g.^{10, 11}).

67 Based on promising findings in animal models and preclinical human studies neuropeptides,
68 including oxytocin (OT), vasopressin or angiotensin II, have been suggested as promising new
69 strategies to regulate fear and anxiety¹²⁻¹⁶. Most previous research in this field has focused on
70 OT, a neuropeptide produced in the hypothalamus, and animal models^{15, 16} as well as preclinical
71 human proof-of-concept studies demonstrated promising effects of OT on regulating negative
72 emotional processing in the domains of fear and anxiety¹⁶⁻²⁰. Some of the effects of OT appear to
73 be specific to social contexts and stimuli, yet in the context of contradictory empirical evidence,
74 debates on the social-specific effects of OT continue^{21, 22}.

75 OT neurons from the hypothalamus project to a wide range of brain regions involved in fear,
76 anxiety as well as social processes, including the amygdala, hippocampus, midbrain and frontal
77 lobe^{5, 23}, and previous studies indicate that intranasal OT can regulate these processes via
78 influencing activity in the amygdala, dorsal anterior cingulate gyrus and medial prefrontal lobe<sup>7,
79 18-20, 24-26</sup>. However, despite the initially promising findings from these studies, the fear and
80 anxiety-reducing effects of OT and the underlying neural circuits have been determined under
81 laboratory experimental contexts that strongly differ from the dynamic contexts during which
82 fear arises in everyday life²⁷. Specifically, these studies combined the intranasal administration of
83 OT with sparsely presented static experimental stimuli (e.g. pictures of fearful faces or scenes)
84 and primarily focused on treatment-induced changes in brain regional activity during fMRI.

85 This approach stands in contrast to contemporary neuroscience models proposing that fear
86 emerges in interaction between subjective appraisal and dynamic changes in the environment<sup>28,
87 29</sup> and that the corresponding mental states are mediated by an intricate interplay among
88 distributed yet interacting brain systems³⁰⁻³². To account for the complexity of subjective
89 affective experiences under ecologically valid conditions and to capture the underlying network-
90 level communication in the brain, recent overarching conceptualizations have proposed the

91 combination of movie stimuli as highly immersive and dynamic stimuli with network-level
92 analyses^{33,34}. Initial empirical studies confirmed that these stimuli can induce highly immersive
93 affective experiences in complex social situations^{35,36} as well as the essential role that network-
94 level communication plays in establishing affective and social experiences under naturalistic
95 contexts^{27,34,37,38}.

96 Mental disorders, including fear-related disorders, have been reconceptualized as network-
97 level disorders that are characterized by dysregulated regional activity as well as network level
98 connectivity (putatively reflecting communication between brain regions)^{32,39,40}. Together with a
99 growing number of studies underscoring the potential of OT to regulate neurofunctional network-
100 level interactions in fear-related networks across species⁴¹⁻⁴⁴, which may be partly explained by
101 the physiological properties of the oxytocin-signaling system, including an axonal release,
102 widespread receptor distribution and considerably longer half-life compared to classical
103 neurotransmitters⁴⁵, these findings indicate the necessity to account for network-level effects to
104 fully determine a regulatory effect of OT on fear experience and its therapeutic potential.

105 Against this background, the present pre-registered between-subjects randomized double-
106 blind placebo-controlled pharmacofMRI study ($n = 67$ healthy male participants) capitalized on
107 recent progress in naturalistic fMRI and network-level analyses to determine whether a single
108 dosage of intranasal OT (1) reduces the subjective experience of fear under highly immersive and
109 ecologically valid conditions, (2) modulates concomitant regional activity in brain systems
110 identified in previous studies, (3) modulates brain communication of the identified regions and
111 on the whole-brain network level, and (4) effects vary as a function of social context. Based on
112 previous studies^{7,18-20} we hypothesized that intranasal OT would decrease subjective fear in
113 naturalistic contexts with more pronounced effects in the social domain while concomitantly
114 enhancing neural activity in regulatory brain regions and inhibiting activity in fear-processing
115 brain regions. On the network level, we expected that OT would enhance communication
116 between emotion-regulation brain regions and the amygdala as well as communication between
117 large-scale networks with pronounced effects in the social fear context.

118

119 **Methods**

120 **Participants**

121 Sixty-nine right-handed male participants with normal or corrected-normal vision were recruited
122 from the University of Electronic Science and Technology of China. The sample size was
123 determined using G*Power v.3.1^{46,47} indicating that 62 participants were required to detect a
124 significant effect on the behavioral level ($f = 0.25$, $\alpha = 0.05$, $\beta = 0.80$, $2 \times 2 \times 2$ mixed ANOVA
125 interaction effect). The present study focused on male subjects to reduce variance related to sex

126 differences in the effects of OT^{48,49} and adhered to validated exclusion criteria (details see
127 supplementary methods). The final sample size was $n = 67$ (mean \pm SD, age = 21.03 ± 1.95
128 years) due to two data from two participants being excluded (withdraw due to personal reasons,
129 technical MRI issues). All participants provided written informed consent, protocols were pre-
130 registered on Clinical Trials.gov (clinicaltrials.gov/ NCT05892939), approved by the ethics
131 committee at the University of Electronic Science and Technology of China (UESTC-
132 1061423041725893) and in line with the latest Declaration of Helsinki.

133 Using a double-blind randomized, placebo-controlled, between-subject pharmacological
134 fMRI design, participants were randomly assigned to receive either a single intranasal dose of
135 oxytocin (OT, 24IU-Sichuan Defeng Pharmaceutical Co. Ltd, China) or a placebo (PLC, same
136 ingredients i.e. sodium chloride and glycerin but without the peptide). The spray bottles were
137 identical and dispensed by an independent researcher based on a computer-generated
138 randomization sequence to ensure double-blinding. The investigators involved in data acquisition
139 and analyses were blinded for group allocation. Following recent recommendations⁵⁰⁻⁵², the fMRI
140 assessment began 45 minutes after treatment administration.

141 To control for pre-treatment between-group differences, participants completed a series of
142 mood and mental health questionnaires (as detailed in **Table 1**). Participants were asked to guess
143 which treatment they had received after the experiment (with a non-significant treatment guess
144 $\chi^2 = 0.39$, $p = 0.53$, confirming successful double-blinding). Additionally, participants were
145 required to complete a surprise recognition task after the experiment that involved presenting
146 stills of the video clips shown during fMRI and new clips to test the attentive processing of the
147 stimuli. All participants achieved a re-recognition accuracy of over 75% and no significant
148 difference in performance was observed between the two treatment groups ($t_{(1,65)} = -0.693$, $p =$
149 0.491).

150 **Naturalistic fear induction paradigm.**

151 The task began 45 minutes after the treatment intervention (see **Fig. 1a**). During the naturalistic
152 fear induction paradigm, participants were instructed to watch a series of video clips attentively
153 and rate their level of fear experience after each clip. The clips lasted 25 seconds and were
154 followed by a 1-3 second jittered fixation cross to separate the stimuli from the rating period.
155 During the 5-second period following each stimulus, participants were asked to report their level
156 of subjective fear on a 9-point Likert scale, with 1 indicating no fear and 9 indicating very strong
157 fear. This was followed by a jittered inter-trial interval of 9-11 seconds, during which a fixation
158 cross was presented (see **Fig. 1b**). A total of 32 short video clips were presented over 2 runs, with
159 each run consisting of 16 randomly presented clips, half of which were neutral and half of which
160 were fear-inducing clips.

161 Given ongoing discussions about the social-specific effects of OT^{53,54}, we carefully pre-
162 selected a balanced set of stimuli that included social as well as non-social fearful or neutral
163 stimuli, respectively. This led to a set of four stimulus categories (fear social clips-FS, fear non-
164 social clips-FNS, neutral social clips-NS, neutral non-social clips-NNS, see **Fig. 1c**). For detailed
165 characterization of the video clips, see Supplementary Methods. The video clips used for the
166 naturalistic fear induction paradigm were selected from a larger database based on stimuli
167 evaluation ratings in an independent sample (n = 20; 10 females; age = 22.65 ± 2.01). Key
168 exclusion criteria for the video clips were reported in supplementary methods. Based on the
169 results of the behavioral ratings (see **Fig. S2**), 8 complimentary video clips were selected for each
170 of the four categories. The task was programmed in Python 3.7 using the PsychoPy package
171 (version 2022.2.4).




Fig. 1 Experimental timeline, paradigm and schematic depiction of stimuli. **a** The timeline of the whole experiment. **b** Naturalistic fear induction and rating paradigm. **c** Example stimuli. In each run, 4 types of video clips were presented (FS, FNS, NS, NNS) according to a randomized order. Abbreviations: OT oxytocin, PLC placebo, fMRI functional magnetic resonance imaging, FS fear social, FNS fear non-social, NS neutral social, NNS neutral non-social. License: Images in 1a and 1b were obtained from Flaticon.com under the free license with attribution.

172 **Effects of OT on subjective fear experience.**

173 To determine the effects of OT on subjective fear in naturalistic contexts and whether they vary
174 as a function of social context, we computed a repeated measures ANOVA with the between-
175 subject factor treatment (OT vs PLC) and the within-subject factors emotion (fear vs neutral) and
176 social (social vs non-social) and the dependent variable fear ratings during fMRI. To initially
177 ensure that the selected video clips were effective in inducing the intended emotions, repeated

178 measures ANOVA (sex was used as the independent variable, while emotion and social were used
179 as repeated variables) were conducted on five rating metrics (see supplementary methods).
180 Analyses were conducted using GraphPad Prism 9.0 (GraphPad Software, Inc., La Jolla, CA), and
181 corresponding effect sizes were computed using JASP 0.18.3.0 (JASP Team, 2019; jasp-stats.org).
182 All ANOVAs and t-tests used false discovery rate (FDR)⁵⁵ recommended by Prism for multiple
183 comparison correction.

184 **MRI data acquisition and preprocessing.**

185 MRI data were collected on a 3.0-T GE Discovery MR750 system (General Electric Medical System,
186 Milwaukee, WI, USA) and preprocessed using FMRIPREP 21.0.0⁵⁶ (RRID: SCR_016216), a Nipype
187 1.6.1 based tool that integrates preprocessing routines from different software packages and
188 SPM 12 (Statistical Parametric Mapping; <http://www.fil.ion.ucl.ac.uk/spm/>; Wellcome Trust
189 Centre for Neuroimaging, detailed in supplementary methods).

190 Next, a voxel-wise general linear model (GLM) was conducted for each participant.
191 Specifically, a first-level model was designed that included separate regressors for the four
192 conditions and the rating period. In line with a previous study²⁸, we removed variance associated
193 with the mean, linear and quadratic trends, the average signal within anatomically-derived CSF
194 mask, the effects of motion estimated during the head-motion correction using an expanded set
195 of 24 motion parameters (six realignment parameters, their squares, their derivatives, and their
196 squared derivatives) and motion spikes (FMRIPREP default: $FD > 0.5\text{mm}$ or standardized
197 $DVARs > 1.5$)⁵⁷.

198 **Effects of OT on fear-related brain activity.**

199 To examine the effects of OT on fear-related neural activity in naturalistic contexts, a GLM-based
200 model was established in SPM 12. The model incorporated five regressors: FS, FNS, NS, NNS, and
201 the rating period. We included the 24 head motion parameters as covariates of no interest. Key
202 first-level contrasts of interest were contrasts that modeled fear in social and non-social contexts
203 separately (i.e., [FS – NS] or [FNS – NNS]) as well as their interaction (i.e., [FS – NS]
204 – [FNS – NNS]). In line with the behavioral analyses, the effects of OT were determined using an
205 ANOVA with the factors emotion and social context, implemented in a partitioned error ANOVA
206 approach that subjected the first level interaction contrast to a voxel-wise two-sample t-test with
207 the factor treatment group on the second level. Based on our hypothesis and previous studies
208 reporting that fear is strongly associated with amygdala, cingulate cortex (particularly middle
209 cingulate cortex, MCC), insula, and ventromedial prefrontal cortex (vmPFC) and that oxytocin
210 mediates its anxiolytic effects via these regions^{14, 22, 27, 58-60}, our analyses focused on atlas-derived
211 bilateral masks for the amygdala, MCC, insula and vmPFC using separate small volume correction
212 (SVC) and family-wise error (FWE) correction⁶¹ applied at peak level.

213 To further disentangle complex interaction effects involving treatment, parameter estimates
214 were extracted using 8mm radius spheres centered at the peak interaction coordinates using
215 Marsbar (<http://marsbar.sourceforge.net/>). The extracted Blood Oxygenation Level Dependent
216 (BOLD) signals were then subjected to appropriate post-hoc tests comparing group differences in
217 each of the separate conditions.

218 Additionally, to determine associations between the behavioral (subjective fear) and neural
219 effects of OT (both activation and functional connectivity between specific brain regions) we
220 conducted correlation analysis using JASP.

221 **Effects of OT on functional communication of the regions identified.**

222 We further examined whether the regions showing altered regional activation following OT also
223 changed their network-level communication via a general Psychophysiological interaction (gPPI)
224 analysis. gPPI examines functional connectivity between brain regions that is contingent on a
225 psychological context. We used the Generalized PPI toolbox⁶² as implemented in SPM 12, to
226 conduct gPPI. This method includes additional task regressors to reduce the likelihood that the
227 functional connectivity estimates are driven simply by co-activation and has been widely used in
228 similar studies^{63, 64}. Based on our results, OT enhanced activation in the left middle cingulate
229 cortex (IMCC) under the three-way interaction (treatment \times emotion \times social), we therefore
230 computed the functional communication of this region (using an 8mm radius which centered in
231 peak Montreal Neurological Institute (MNI), $x, y, z = -7, -3, 30$) with other voxels in the whole
232 brain under the two-way interaction of emotion and social, and a two-sample t-test was
233 conducted to confirm the treatment effect of OT. Based on previous studies reporting effects of
234 OT on the functional communication of the amygdala^{48, 49}, separate atlas-derived bilateral masks
235 for the amygdala, MCC, insula and vmPFC were used for SVC analyses with FWE correction⁶¹
236 applied at peak level.

237 Marsbar was used to extract information communications between other regions and the
238 seed region to further disentangle complex interaction effects involving treatment. The extracted
239 functional connectivity signals were then subjected to compare the treatment effect under four
240 conditions by using two-sample t-tests separately.

241 **Effects of OT on large-scale brain network functional connectivity.**

242 Given that several studies reported the effects of OT on large-scale network organization of the
243 brain^{65, 66}, we examined OT effects on the whole-brain network level. To this end, time-series of
244 each region of interest (ROI) was extracted according to the template including 463 ROIs across
245 the whole brain (see supplementary methods), resulting in BOLD time series of the size of $r \times t$ (r
246 was the number of ROIs and t was the BOLD time series length) for each subject per run. A matrix
247 of size $r \times r$ was obtained by calculating Pearson's correlation between the average BOLD time
248 series of each pair of ROIs. Additionally, Fisher's z-transform was applied to improve the

249 normality of the correlation coefficients. The brain regions can be divided into nine networks
250 based on their functional divisions, and the neural activities of each network's regions were
251 averaged to calculate network functional connectivity.

252 During each run, four types of video clips were presented in a pseudo-randomized order. The
253 onset time of each video clip was shifted by 3 TRs to account for hemodynamic lag. To extract
254 neural activity time series for a specific condition, we used the time points and durations
255 specified for the appearance of different trials of the same type. This resulted in four $r \times d$
256 matrices (where r is the number of ROIs and d is the BOLD time series length of each condition).
257 Additionally, we obtained the $r \times r$ matrix between ROIs and the $n \times n$ matrix (where n is the
258 number of networks) between brain networks for different conditions.

259 After performing Fisher-Z transformation on the network functional connectivity matrices
260 for different conditions, matrices of Z-values corresponding to specific conditions
261 (Z_{FS} , Z_{FNS} , Z_{NS} , Z_{FNS}) are obtained. It is important to note that r values are not additive or
262 subtractive, but Z scores are summative. Matrix of Z-values corresponding to particular contrasts
263 (e.g. Z_{FS-NS}) can be computed by subtract the matrices of Z-values corresponding to different
264 conditions (e.g. $Z_{FS}-Z_{NS}$)^{67, 68}. Therefore, each participant in both groups would have their own
265 subtracted Z-values matrix under specific contrasts (Z_{FS-NS} , $Z_{FNS-NNS}$). We then conducted two-
266 sample t-tests on each pair of network-level functional connectivity to determine the treatment
267 effect.

268 **Effects of OT on whole-brain functional connectivity.**

269 To further investigate the impact of OT on a finer spatial scale, we analyzed whole-brain
270 functional connectivity using paired t-tests for key contrasts (FS – NNS and FNS – NNS)
271 separately for the two groups. We applied FDR correction ($p_{FDR-corrected} < 0.05$) to identify the
272 most relevant functional connections for each contrast. A Mantel test^{69, 70} was performed on the
273 FDR-corrected functional connectivity matrices of the two groups, under specific contrasts, to
274 assess their similarity. Furthermore, to investigate treatment-specific effects on functional
275 connectivity strength at the whole-brain level, we transformed the upper triangular data of the t-
276 value matrices of the two groups under specific contrast into two $(r \times (r - 1)) / 2$ by 1 feature
277 vectors, and performed Welch's t-test between them.

278

279 **Results**

280 **Demographics and potential confounders.**

281 The OT (n = 33) and PLC (n = 34) groups were comparable with respect to socio-demographics,
282 mood and mental health indices arguing against nonspecific treatment effects (**Table 1**, all $ps >$
283 0.10).

Table 1. Demographics and potential confounders in the two treatment groups.

	Time	OT(M ± SD)	PLC(M ± SD)	t	p
Age		21.30 ± 2.05	20.76 ± 1.83	1.13	0.26
BDI II	Before	4.70 ± 3.83	5.38 ± 5.40	-0.60	0.55
BAI	Before	2.36 ± 2.56	2.53 ± 3.75	-0.21	0.83
LSAS	Before	31.36 ± 20.35	26.15 ± 19.47	1.07	0.29
SAI	Before	34.79 ± 6.63	33.15 ± 9.37	0.83	0.41
TAI	Before	37.82 ± 7.30	37.97 ± 9.99	-0.07	0.94
ERQ-Reappraisal	Before	31.00 ± 3.98	30.74 ± 4.15	0.27	0.79
ERQ-Suppression	Before	15.85 ± 4.72	14.82 ± 4.41	0.92	0.36
PANAS-P	Before ¹	28.85 ± 6.05	28.47 ± 7.17	0.23	0.82
	2 - 1	-6.12 ± 6.71	-4.06 ± 5.18	-1.41	0.16
	Treatment peak ²	22.73 ± 5.95	24.41 ± 6.90	-1.07	0.29
	3 - 2	-2.85 ± 5.50	-1.62 ± 5.39	-0.93	0.36
	After experiment ³	19.88 ± 6.71	22.79 ± 7.71	-1.65	0.10
PANAS-N	3 - 1	-8.97 ± 7.12	-5.68 ± 7.53	-1.84	0.07
	Before ¹	15.09 ± 5.17	14.09 ± 4.82	0.82	0.41
	2 - 1	-3.24 ± 4.70	-3.06 ± 4.06	-0.17	0.87
	Treatment peak ²	11.85 ± 3.17	11.03 ± 2.32	1.21	0.23
	3 - 2	1.33 ± 2.97	1.65 ± 2.62	-0.46	0.65
	After experiment ³	13.18 ± 4.15	12.68 ± 3.86	0.52	0.61
	3 - 1	-1.91 ± 6.07	-1.41 ± 5.51	-0.35	0.73

Values presented here as mean ± standard deviation (M ± SD). *BDI II* Beck Depression Inventory II, *BAI* Beck Anxiety Index, *LSAS* Liebowitz Social Anxiety Scale, *STAI* Spielberger State-Trait Anxiety Inventory, *ERQ* Emotion Regulation Questionnaire, *PANAS* Positive and Negative Affect Schedule, *OT* oxytocin, *PLC* placebo.

284 **OT reduced subjective fear experience in naturalistic contexts, particularly in social**
 285 **contexts.**

286 The ANOVA revealed a significant main effect of emotion ($F_{(1,65)} = 1434, p < 0.0001, \eta_p^2 =$
 287 $0.957, \text{Fig. 2a}$) such that participants rated subjective fear considerably higher during fear trials
 288 (FS and FNS) than neutral ones, and a significant main effect of social ($F_{(1,65)} = 76.81, p < 0.0001,$
 289 $\eta_p^2 = 0.542, \text{Fig. 2a}$) reflecting lower fear during social trials (FS and NS) compared with non-
 290 social trials. With respect to the effects of OT we found a significant interaction effect between
 291 treatment and emotion ($F_{(3,65)} = 4.064, p = 0.048, \eta_p^2 = 0.059, \text{Fig. 2a}$), with post hoc tests
 292 indicating that OT significantly decreased fear experience in response to fearful stimuli in
 293 naturalistic social contexts while the effects sizes indicated a stronger fear reduction in social
 294 contexts ($t_{(1,65)} = -3.038, p = 0.0027, \text{Cohen's } d = -0.742$ under FS while $t_{(1,65)} = -1.991, p =$
 295 $0.048, \text{Cohen's } d = -0.487$ under FNS, **Fig. 2b**). Finally, the interaction between emotion and
 296 social was significant ($F_{(3,65)} = 53.15, p < 0.0001, \eta_p^2 = 0.45, \text{Fig. 2a}$) reflecting that
 297 participants reported generally lower fear experience in social fear contexts. The main effect of
 298 treatment and other interactions were not significant. Together the results partly support that OT

299 can reduce subjective fear in naturalistic situations and that the effects are more pronounced in
 300 social fear contexts.




Fig. 2 The effects of OT on behavioral fear rating and cingulate activity. **a** OT reduced subjective fear rating in naturalistic situations particularly in contexts, **b** OT effects on fear rating under four conditions separately, **c** OT but not PLC could strengthen the activation in the left middle cingulate cortex (IMCC) under the interaction of valence and social. Particularly, **d** OT specifically increased the activation in IMCC under FS but not other conditions. **e** The activation in IMCC was significantly negatively correlated with subjective fear experience in OT group but not PLC group. OT oxytocin, PLC placebo, FS fear social, FNS fear non-social, NS neutral social, NNS neutral non-social. **** $p_{FDR-corrected} < 0.0001$, *** $p_{FDR-corrected} < 0.001$, ** $p_{FDR-corrected} < 0.01$, * $p_{FDR-corrected} < 0.05$, ns not significant.

301 **OT enhanced middle cingulate activation in the social fear contexts.**

302 We initially examined brain regions participating in fear processing under naturalistic contexts
 303 with different social features compared with neutral control conditions, a series of corresponding
 304 voxel-wise one-sample t-tests conducted in the PLC group confirmed previous studies, suggesting
 305 that visual and temporal regions were strongly engaged during exposure to dynamic fear movie
 306 clips irrespective of social features (**Fig. S3**). Examining treatment effects revealed a significant
 307 interaction between treatment \times emotion \times social located in the left middle cingulate cortex
 308 (peak MNI, x, y, z = -7, -3, 30, $t_{(1,65)} = 3.67$, k = 33, $p_{FWE-peak(svc)} = 0.019$, **Fig. 2c**), with post-hoc t-
 309 tests on extracted activity measures from this region indicating that compared to PLC, OT
 310 selectively enhanced activation in this region for FS ($t_{(1,65)} = 2.761$, $p = 0.007$, Cohen's $d = 0.675$,
 311 **Fig. 2d**) but not other conditions (all $p_s > 0.05$, **Fig. 2d**). Examining associations between IMCC
 312 activation (extracted parameter estimates) and subjective fear experience revealed a significant
 313 negative association in the OT ($r = -0.418$, $p = 0.016$, **Fig. 2e**) but not in PLC group ($r = 0.090$, $p =$

314 0.611, **Fig. 2e**). A Fisher r - z transformation indicated that these correlation coefficients were
 315 significantly different between the OT and PLC groups ($Z = -2.09$, two-tailed $p = 0.037$).
 316 **OT enhanced MCC-amygdala functional communication consistently in the social**
 317 **fear contexts.**
 318 Examining OT effects on the functional communication of the IMCC revealed a significant
 319 interaction effect between treatment \times emotion \times social located in the right amygdala (rAmy)
 320 (peak MNI, $x, y, z = 22, -7, 13$, $t_{(1,65)} = 3.81$, $k = 19$, $p_{\text{FWE-peak}(svc)} = 0.021$, **Fig. 3a**), with post-hoc t -
 321 tests indicating that OT relative to PLC selectively enhanced IMCC-rAmy coupling in social fear
 322 contexts ($t_{(1,65)} = 2.70$, $p = 0.009$, Cohen's $d = 0.66$, **Fig. 3b**) but not other contexts (all p s > 0.05 ,
 323 FDR-corrected, **Fig. 3b**), confirming social fear-specific effects of OT on the neural level. In
 324 addition, we found that IMCC-rAmy functional coupling was significantly negatively associated
 325 with subjective fear experience in the OT ($r = -0.392$, $p = 0.024$, **Fig. 3c**) but not PLC group ($r = -$
 326 0.084 , $p = 0.638$, **Fig. 3c**, Fisher r -to- z transformation revealed a trend-to-significant difference
 327 between the treatment groups, $Z = -1.29$, one-tailed $p = 0.099$).




Fig. 3 OT strengthened IMCC-rAmy communication specifically in social fear contexts. **a** Interaction effect between treatment \times emotion \times social on IMCC connectivity with the right amygdala **b** OT specifically increased functional connectivity between IMCC and rAmy in the FS contexts but not other conditions and **c** The functional connectivity between IMCC and rAmy was significantly negatively correlated with subjective fear experience in OT group but not PLC group. OT oxytocin, PLC placebo, FS fear social, FNS fear non-social, NS neutral social, NNS neutral non-social. ** $p_{\text{FDR-corrected}} < 0.01$, * $p_{\text{FDR-corrected}} < 0.05$, # $p_{\text{uncorrected}} < 0.05$.

328

329

330 **OT enhanced FPN-DAN and DMN-DAN coupling during social fear contexts.**

331 Examining the effects of OT on the large-scale network level using separate two-sample t-tests on
 332 the matrices of z-values for the two main contrasts of interest (FS – NS, FNS – NNS) and
 333 following mantel test revealed that OT significantly affected network functional connectivity
 334 differently under two contexts ($\rho_{\text{mantel test}} = -0.1333, p > 0.05$). Specifically, compared to PLC (all
 335 $p_s > 0.05$, **Fig. 4f**), OT significantly enhanced the functional communication between FPN and
 336 DAN ($t_{(1,65)} = 2.75, p = 0.0077$, Cohen's $d = 0.672$, **Fig. 4e**) as well as between DMN and DAN
 337 ($t_{(1,65)} = 2.02, p = 0.048$, Cohen's $d = 0.493$, **Fig. 4e**) under the social fear but not the non-social
 338 fear contexts.




Fig. 4 OT enhanced functional connectivity on the level of large-scale networks. a b c d Flow of z-value matrix calculation for the degree of response functional connectivity under specific contrasts. (1) The Fisher r-z matrices of each condition for each participant were subtracted to yield a new matrix of z-value corresponding to the contrast (e.g. $z_{FS} - z_{NS} = z_{FS} - z_{NS}$). (2) New matrices of z-value corresponding to a specific contrast were generated for each participant in each group, which were used as features in a two-sample t-test to derive the between-group differences under the specified contrast. **e** OT significantly strengthened the functional connectivity between FPN and DAN as well as DMN and DAN in the fear social-related contrast **f** but not in the fear non-social-related contrast. OT oxytocin, PLC placebo, FS fear social, FNS fear non-social, NS neutral social, NNS neutral non-social, VN visual network, SMN somatomotor network, DAN dorsal attention network, VAN ventral attention network, LN limbic network, FPN frontoparietal network, DMN default mode network, SCT subcortical network, B/C brainstem and cerebellum. ## $p_{\text{un-corrected}} < 0.01$, # $p_{\text{un-corrected}} < 0.05$.

339 **OT modulated whole-brain functional connectivity in the social fear context.**

340 We further conducted exploratory analyses to examine whether OT changes brain-wide
 341 communications. Results showed that while under PLC only few positive connections increased
 342 activity during the FS versus NS contrast (**Fig. 5a**), OT induced a more widespread connectivity

343 between several brain regions (**Fig. 5b**). Under the FNS versus NNS contrast, the PLC group
344 exhibited wide-spread connectivity (**Fig. 5c**), with no obvious changes following OT (**Fig. 5d**).
345 Further Mantel tests and Welch's t-test were conducted on the t-value matrices (FS – NS and
346 FNS – NNS) between both groups showed significant modulating effects of OT under both
347 contrasts ($\rho_{\text{mantel test}} = 0.0335$, $t_{(1,65)} = 9.05$, $p < 0.0001$ under FS – NS, $\rho_{\text{mantel test}} = 0.208$,
348 $t_{(1,65)} = -2.51$, $p = 0.012$ under FNS – NNS), particularly under the fear social contexts.




Fig. 5 Comparison between treatment groups for whole-brain functional connectivity during social and non-social fear separately. Under fear social contexts, **a** PLC group showed a sparse connectivity between brain regions **b** the OT group exhibited stronger functional interactions at the whole-brain level. In contrast, under the fear non-social context **c** PLC and **d** OT groups showed similar whole-brain functional connectivity patterns. OT oxytocin, PLC placebo, FS fear social, FNS fear non-social, NS neutral social, NNS neutral non-social, VN visual network, SMN somatomotor network, DAN dorsal attention network, VAN ventral attention network, LN limbic network, FPN frontoparietal network, DMN default mode network, SCT subcortical network, B/C brainstem and cerebellum.

349

350 Discussion

351 The present study determined the acute behavioral and neural effects of a single intranasal OT
352 administration on subjective fear experience in a naturalistic context that resembles dynamic fear
353 processing in social and non-social contexts in a close-to-real life setting. On the behavioral level,
354 OT decreased the experience of subjective fear across social and non-social contexts, supporting
355 a fear-regulating potential of OT under dynamic and ecologically valid conditions. Mirroring the
356 stronger effect sizes of the OT-induced fear reduction in social contexts, neural effects of OT were
357 primarily observed in social fear contexts, such that OT enhanced regional activation in the left

358 MCC and its communication with the contralateral amygdala specifically during fear in social
359 contexts with both neural indices exhibiting a negative association with subjective fear following
360 OT but not PLC. Exploratory network-level analyses further revealed that OT significantly
361 enhanced the functional connectivity between the DAN and the FPN/DMN, respectively, and
362 brain-wide communication selectively in social fear contexts. Together, the findings indicate that
363 a single dose of intranasal OT has the potential to decrease fear in close-to-real life settings by
364 enhancing IMCC activation and its communication with the amygdala while concomitantly
365 affecting network-level communication of the DAN with brain networks involved in regulatory
366 control (FPN^{71, 72}) and social processing (DMN^{73, 74}) as well as brain-wide functional
367 communication.

368 Several previous studies in rodents and humans suggested a fear- and anxiety-reducing
369 potential of OT, however, results remained inconsistent. Studies have described a promising fear-
370 and anxiety-reducing neurofunctional profile of OT across species, yet the neural effects on
371 amygdala-related circuits were often observed in the absence of changes in subjective fear
372 experience or under experimental laboratory settings with limited ecological validity^{15, 17-20, 75}.

373 In the context of increasing attempts to enhance the ecological validity of neuroimaging
374 research using dynamic movie stimuli^{27, 28, 76}, we here combined naturalistic fMRI employing
375 fear-inducing movie clips with a pre-registered randomized double-blind placebo-controlled OT-
376 administration trial. Across pilot experiments and treatment studies, the procedure induced a
377 highly immersive and comparably strong experience of fear under close-to-real life conditions.
378 Importantly, OT decreased subjective fear experience in the more naturalistic context with small
379 or moderate effect sizes in the non-social or social context, respectively. Although the
380 pronounced fear-reducing effects of OT in the social context may partly reflect the generally more
381 moderate fear experience reported by our participants in this context, pronounced effects of OT
382 in social contexts have been conceptualized in a number of overarching theories and have been
383 reported in several previous studies^{21, 22, 77} including studies reporting decreased subjective
384 anxiety⁷⁸. The latter hypothesis on the social-specific effects of OT is also mirrored in the brain
385 functional findings, such that the neurofunctional effects were selectively observed during fear
386 experiences in social contexts.

387 With respect to regional activation, OT increased the activation of the left middle cingulate
388 cortex (IMCC). The MCC represents a highly integrative hub that has been involved in both, fear
389 evaluation^{5, 60, 79, 80} as well as the cognitive control of negative affective states including fear^{81, 82}.
390 Concomitantly, OT enhanced functional connectivity from the IMCC to the contralateral amygdala
391 (rAmy), a pathway that has been previously involved in implementing top-down inhibitory control
392 over excessive fear-related amygdala engagement^{60, 80, 83}. Effects of OT on this circuitry have been
393 previously reported in the context of reduced subjective anxiety in individuals with PTSD⁸⁴ and in

394 response to static fearful faces in patients with generalized social anxiety disorders²⁵. Exploring
395 brain-behavior associations further revealed that OT established a negative association between
396 higher activity and connectivity in this circuit and subjective fear, underscoring the behavioral
397 relevance of the OT-induced neurofunctional changes. Together, our findings suggest that OT
398 exerts its fear-regulating effects under naturalistic contexts via enhancing MCC engagement and
399 control over the amygdala.

400 On the large-scale network level, OT significantly enhanced the functional connectivity of
401 the DAN with the FPN as well as the DMN in the social fear contexts. The DAN is centered around
402 the intraparietal sulcus and the frontal eye fields and plays a pivotal role in top-down or goal-
403 directed control of attention⁸⁵⁻⁸⁷, while the FPN supports goal-directed actions and cognitive
404 control^{71, 88, 89} and the DMN supports self-referential^{90, 91} and social processing^{73, 74}, with more
405 recent findings additionally suggesting a role in emotional experience in dynamic naturalistic
406 contexts^{92, 93}. While studies have demonstrated the effects of OT on the interaction between
407 these large-scale networks during the task-free state^{65, 94}, the present findings underscore the
408 behavioral relevance of these effects of OT in terms of regulating emotional processes in social
409 contexts. Together with previous studies suggesting an association between dysfunctional
410 interaction between these large-scale networks and emotional dysregulations in anxiety and
411 fear-related disorders^{32, 91}, the present findings support a potential therapeutic potential of OT
412 for these disorders^{32, 95, 96}.

413 Network-level analyses that explored the effects of OT on the fine-grained level of brain-
414 wide connectivity patterns suggested that OT may broadly facilitate brain-wide exchange of
415 information within and across networks particularly between the FPN and DMN in social fear
416 contexts. The results align with recent findings suggesting that emotional processes such as fear
417 and anxiety are processed in distributed networks and their interactions^{27, 34, 97} as well as the
418 distributed network-level properties and effects of the OT signaling system^{41, 98, 99}. These findings
419 underscore that OT may exert its effects on human emotion processing under complex
420 naturalistic conditions via regulating extensive network-level interactions. Together with
421 increasing the reconceptualization and increasing evidence indicating that mental disorders are
422 not related to dysfunctions of a single brain region or pathway but rather dysregulated brain-wide
423 communication^{32, 91, 100}, these findings may further underscore the therapeutic potential of the
424 OT signaling system.

425 Findings have to be considered in the context of limitations of the present design, including
426 (1) to avoid variations in the effects of OT related to sex^{48, 49}, we only focused on male
427 participants and future studies need to test generalization to females, (2) the study employed a
428 proof-of-concept design in healthy subjects and future studies need to validate the effects of OT
429 in populations with pathological fear and anxiety, (3) despite extensive pre-study testing the

430 videos of the social and non-social category differed in terms of the level of fear induced which
431 partly limits conclusions regarding social-specific effects of OT, (4) the videos included
432 homogenous brief episodes of fear and future studies need to examine effects of OT on fear
433 during longer time scales and longer episodes with dynamic fear^{27,28}.

434 Taken together, this study demonstrated that OT can reduce subjective fear experience
435 under naturalistic conditions via enhancing IMCC engagement and its regulatory control over the
436 amygdala as well as enhancing communication between large-scale networks and brain-wide
437 communication. These findings consistently indicate a high translational therapeutic potential of
438 OT to regulate fear in dynamic and close-to-real life environments. Effects were pronounced or
439 restricted to the social contexts, supporting the role that OT may play in social contexts, and
440 rendering OT as a promising treatment for social context-specific fear experiences, e.g. in social
441 anxiety disorders. Findings indicate that OT may be used as a novel therapeutic strategy to
442 regulate excessive subjective fear symptoms in mental disorders^{7,17,24} or may help to prevent the
443 development of these disorders during early stages or promote long-term recovery⁹⁴ via
444 improving the quality of life, and reduce the social and economic burden related to fear-related
445 disorders.

446

447 **Acknowledgement**

448 This work was supported by the China MOST2030 Brain Project (Grant No. 2022ZD0208500), the
449 National Natural Science Foundation of China (Grants No. 32250610208, 82271583-BB), the
450 National Key Research and Development Program of China (Grant No. 2018YFA0701400-BB), the
451 Natural Science Foundation of Sichuan Province (Grant number 2022NSFSC1375-WZ) and a start-
452 up grant from The University of Hong Kong. Disclaimer: Any opinions, findings, conclusions or
453 recommendations expressed in this publication do not reflect the views of the Government of
454 the Hong Kong Special Administrative Region or the Innovation and Technology Commission.

455

456 **Author contributions**

457 KF and BB¹ designed the study. KF, ZZ and DL conducted the experiment and collected the data.
458 KF, SX, WZ, ZL performed the data analysis with the help of TX, YZ, XZ, CL, JW, LW, JH and BB². KF
459 and BB¹ wrote the manuscript. SX, FZ, KK, TX, YZ, ZL and WZ critically revised the manuscript
460 draft.

461 Note: BB¹, Benjamin Becker; BB², Bharat Biswal.

462

463 **Competing interests**

464 The authors declare no competing interests.

465

466 **References**

- 467 1. Osakada T, Yan R, Jiang Y, Wei D, Tabuchi R, Dai B *et al.* A dedicated hypothalamic oxytocin circuit
468 controls aversive social learning. *Nature* 2024.
- 469 2. Akinrinade I, Kareklas K, Teles MC, Reis TK, Glikberg M, Petri G *et al.* Evolutionarily conserved
470 role of oxytocin in social fear contagion in zebrafish. *Science* 2023; **379**(6638): 1232-1237.
- 471 3. Faul L, Stjepanović D, Stivers JM, Stewart GW, Graner JL, Morey RA *et al.* Proximal threats
472 promote enhanced acquisition and persistence of reactive fear-learning circuits. *Proceedings of the*
473 *National Academy of Sciences* 2020; **117**(28): 16678-16689.
- 474 4. Becker B, Zhou F. Neural Processing of Fear – From Animal Models to Human Research. 2020.
- 475 5. Zhou F, Zhao W, Qi Z, Geng Y, Yao S, Kendrick KM *et al.* A distributed fMRI-based signature for the
476 subjective experience of fear. *Nature Communications* 2021; **12**(1): 6643.
- 477 6. Bramson B, Meijer S, van Nuland A, Toni I, Roelofs K. Anxious individuals shift emotion control
478 from lateral frontal pole to dorsolateral prefrontal cortex. *Nature Communications* 2023; **14**(1): 4880.
- 479 7. Kreuder A-K, Scheele D, Schultz J, Hennig J, Marsh N, Dellert T *et al.* Common and dissociable
480 effects of oxytocin and lorazepam on the neurocircuitry of fear. *Proceedings of the National Academy*
481 *of Sciences* 2020; **117**(21): 11781-11787.
- 482 8. Szuhany KL, Simon NM. Anxiety Disorders: A Review. *JAMA* 2022; **328**(24): 2431-2445.
- 483 9. Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for
484 generalised anxiety disorder: a systematic review and network meta-analysis. *The Lancet* 2019;
485 **393**(10173): 768-777.
- 486 10. Taschereau-Dumouchel V, Cortese A, Chiba T, Knotts JD, Kawato M, Lau H. Towards an
487 unconscious neural reinforcement intervention for common fears. *Proceedings of the National*
488 *Academy of Sciences* 2018; **115**(13): 3470-3475.
- 489 11. Zhao Z, Yao S, Li K, Sindermann C, Zhou F, Zhao W *et al.* Real-Time Functional Connectivity-
490 Informed Neurofeedback of Amygdala-Frontal Pathways Reduces Anxiety. *Psychotherapy and*
491 *Psychosomatics* 2019; **88**(1): 5-15.
- 492 12. Paul JM, Raül A, Rene H, Tiffany RL, Moriel Z, Joanna D. Limbic Neuropeptidergic Modulators of
493 Emotion and Their Therapeutic Potential for Anxiety and Post-Traumatic Stress Disorder. *The Journal of*
494 *Neuroscience* 2021; **41**(5): 901.
- 495 13. Zhang R, Zhao W, Qi Z, Xu T, Zhou F, Becker B. Angiotensin II Regulates the Neural Expression of
496 Subjective Fear in Humans: A Precision Pharmaco-Neuroimaging Approach. *Biological Psychiatry:*
497 *Cognitive Neuroscience and Neuroimaging* 2023; **8**(3): 262-270.
- 498 14. Zhou F, Geng Y, Xin F, Li J, Feng P, Liu C *et al.* Human Extinction Learning Is Accelerated by an
499 Angiotensin Antagonist via Ventromedial Prefrontal Cortex and Its Connections With Basolateral
500 Amygdala. *Biol Psychiat* 2019; **86**(12): 910-920.
- 501 15. Knobloch HS, Charlet A, Hoffmann Lena C, Eliava M, Khrulev S, Cetin Ali H *et al.* Evoked Axonal
502 Oxytocin Release in the Central Amygdala Attenuates Fear Response. *Neuron* 2012; **73**(3): 553-566.
- 503 16. Neumann ID, Slattery DA. Oxytocin in General Anxiety and Social Fear: A Translational Approach.
504 *Biol Psychiat* 2016; **79**(3): 213-221.
- 505 17. Eckstein M, Becker B, Scheele D, Scholz C, Preckel K, Schlaepfer TE *et al.* Oxytocin Facilitates the
506 Extinction of Conditioned Fear in Humans. *Biol Psychiat* 2015; **78**(3): 194-202.
- 507 18. Kou J, Zhang Y, Zhou F, Gao Z, Yao S, Zhao W *et al.* Anxiolytic Effects of Chronic Intranasal
508 Oxytocin on Neural Responses to Threat Are Dose-Frequency Dependent. *Psychotherapy and*
509 *Psychosomatics* 2022; **91**(4): 253-264.
- 510 19. Xin F, Zhou X, Dong D, Zhao Z, Yang X, Wang Q *et al.* Oxytocin Differentially Modulates Amygdala
511 Responses during Top-Down and Bottom-Up Aversive Anticipation. *Adv Sci* 2020; **7**(16): 2001077.
- 512 20. Liu C, Lan C, Li K, Zhou F, Yao S, Xu L *et al.* Oxytocinergic Modulation of Threat-Specific Amygdala
513 Sensitization in Humans Is Critically Mediated by Serotonergic Mechanisms. *Biological Psychiatry:*
514 *Cognitive Neuroscience and Neuroimaging* 2021; **6**(11): 1081-1089.
- 515 21. Shamay-Tsoory SG, Abu-Akel A. The Social Salience Hypothesis of Oxytocin. *Biol Psychiat* 2016;
516 **79**(3): 194-202.
- 517 22. Yao S, Zhao W, Geng Y, Chen Y, Zhao Z, Ma X *et al.* Oxytocin Facilitates Approach Behavior to
518 Positive Social Stimuli via Decreasing Anterior Insula Activity. *Int J Neuropsychoph* 2018; **21**(10): 918-
519 925.
- 520 23. Oliver JR, Alexandra CP, Brian C, Christian G. The translational neural circuitry of anxiety. *Journal*
521 *of Neurology, Neurosurgery & Psychiatry* 2019; **90**(12): 1353.

- 522 24. Scheele D, Lieberz J, Goertzen-Patin A, Engels C, Schneider L, Stoffel-Wagner B *et al.* Trauma
523 Disclosure Moderates the Effects of Oxytocin on Intrusions and Neural Responses to Fear.
524 *Psychotherapy and Psychosomatics* 2019; **88**(1): 61-63.
- 525 25. Gorka SM, Fitzgerald DA, Labuschagne I, Hosanagar A, Wood AG, Nathan PJ *et al.* Oxytocin
526 Modulation of Amygdala Functional Connectivity to Fearful Faces in Generalized Social Anxiety
527 Disorder. *Neuropsychopharmacology* 2015; **40**(2): 278-286.
- 528 26. Eckstein M, Scheele D, Patin A, Preckel K, Becker B, Walter A *et al.* Oxytocin Facilitates Pavlovian
529 Fear Learning in Males. *Neuropsychopharmacology* 2016; **41**(4): 932-939.
- 530 27. Feng Z, Ran Z, Shuxia Y, Debo D, Pan F, Georg K *et al.* Capturing dynamic fear experiences in
531 naturalistic contexts: An ecologically valid fMRI signature integrating brain activation and connectivity.
532 *bioRxiv* 2024: 2023.2008.2018.553808.
- 533 28. Chang LJ, Jolly E, Cheong JH, Rapuano KM, Greenstein N, Chen P-HA *et al.* Endogenous variation
534 in ventromedial prefrontal cortex state dynamics during naturalistic viewing reflects affective
535 experience. *Science Advances*; **7**(17): eabf7129.
- 536 29. Meer JNvd, Breakspear M, Chang LJ, Sonkusare S, Cocchi L. Movie viewing elicits rich and reliable
537 brain state dynamics. *Nature Communications* 2020; **11**(1): 5004.
- 538 30. Adolphs R. How should neuroscience study emotions? by distinguishing emotion states,
539 concepts, and experiences. *Soc Cogn Affect Neur* 2017; **12**(1): 24-31.
- 540 31. Pessoa L. A Network Model of the Emotional Brain. *Trends in Cognitive Sciences* 2017; **21**(5): 357-
541 371.
- 542 32. Wen Z, Seo J, Pace-Schott EF, Milad MR. Abnormal dynamic functional connectivity during fear
543 extinction learning in PTSD and anxiety disorders. *Molecular Psychiatry* 2022; **27**(4): 2216-2224.
- 544 33. Eickhoff SB, Milham M, Vanderwal T. Towards clinical applications of movie fMRI. *NeuroImage*
545 2020; **217**: 116860.
- 546 34. Saarimäki H, Glerean E, Smirnov D, Mynttinen H, Jääskeläinen IP, Sams M *et al.* Classification of
547 emotion categories based on functional connectivity patterns of the human brain. *NeuroImage* 2022;
548 **247**: 118800.
- 549 35. de Vries IEJ, Wurm MF. Predictive neural representations of naturalistic dynamic input. *Nature*
550 *Communications* 2023; **14**(1): 3858.
- 551 36. Redcay E, Moraczewski D. Social cognition in context: A naturalistic imaging approach.
552 *NeuroImage* 2020; **216**: 116392.
- 553 37. Lee J-J, Kim HJ, Čeko M, Park B-y, Lee SA, Park H *et al.* A neuroimaging biomarker for sustained
554 experimental and clinical pain. *Nature Medicine* 2021; **27**(1): 174-182.
- 555 38. Hayoung S, Bo-yong P, Hyunjin P, Won Mok S. Cognitive and Neural State Dynamics of Narrative
556 Comprehension. *The Journal of Neuroscience* 2021; **41**(43): 8972.
- 557 39. Etkin A, Maron-Katz A, Wu W, Fonzo GA, Huemer J, Vértes PE *et al.* Using fMRI connectivity to
558 define a treatment-resistant form of post-traumatic stress disorder. *Science Translational Medicine*
559 2019; **11**(486): eaal3236.
- 560 40. Xu X, Dai J, Chen Y, Liu C, Xin F, Zhou X *et al.* Intrinsic connectivity of the prefrontal cortex and
561 striato-limbic system respectively differentiate major depressive from generalized anxiety disorder.
562 *Neuropsychopharmacology* 2021; **46**(4): 791-798.
- 563 41. Jiang X, Ma X, Geng Y, Zhao Z, Zhou F, Zhao W *et al.* Intrinsic, dynamic and effective connectivity
564 among large-scale brain networks modulated by oxytocin. *NeuroImage* 2021; **227**: 117668.
- 565 42. Zhao Z, Ma X, Geng Y, Zhao W, Zhou F, Wang J *et al.* Oxytocin differentially modulates specific
566 dorsal and ventral striatal functional connections with frontal and cerebellar regions. *NeuroImage*
567 2019; **184**: 781-789.
- 568 43. Liu N, Hadj-Bouziane F, Jones KB, Turchi JN, Averbek BB, Ungerleider LG. Oxytocin modulates
569 fMRI responses to facial expression in macaques. *Proceedings of the National Academy of Sciences*
570 2015; **112**(24): E3123-E3130.
- 571 44. Wahis J, Baudon A, Althammer F, Kerspern D, Goyon S, Hagiwara D *et al.* Astrocytes mediate the
572 effect of oxytocin in the central amygdala on neuronal activity and affective states in rodents. *Nat*
573 *Neurosci* 2021; **24**(4): 529-541.
- 574 45. Bethlehem RAI, van Honk J, Auyeung B, Baron-Cohen S. Oxytocin, brain physiology, and
575 functional connectivity: A review of intranasal oxytocin fMRI studies. *Psychoneuroendocrinol* 2013;
576 **38**(7): 962-974.
- 577 46. Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G*Power 3.1: Tests for
578 correlation and regression analyses. *Behavior Research Methods* 2009; **41**(4): 1149-1160.

- 579 47. Liu Y, Li S, Lin W, Li W, Yan X, Wang X *et al.* Oxytocin modulates social value representations in the
580 amygdala. *Nat Neurosci* 2019; **22**(4): 633-641.
- 581 48. Gao S, Becker B, Luo L, Geng Y, Zhao W, Yin Y *et al.* Oxytocin, the peptide that bonds the sexes
582 also divides them. *Proceedings of the National Academy of Sciences* 2016; **113**(27): 7650-7654.
- 583 49. Ma X, Zhao W, Luo R, Zhou F, Geng Y, Xu L *et al.* Sex- and context-dependent effects of oxytocin
584 on social sharing. *NeuroImage* 2018; **183**: 62-72.
- 585 50. Watanabe T, Abe O, Kuwabara H, Yahata N, Takano Y, Iwashiro N *et al.* Mitigation of
586 Sociocommunicational Deficits of Autism Through Oxytocin-Induced Recovery of Medial Prefrontal
587 Activity A Randomized Trial. *Jama Psychiat* 2014; **71**(2): 166-175.
- 588 51. Spengler FB, Schultz J, Scheele D, Essel M, Maier W, Heinrichs M *et al.* Kinetics and Dose
589 Dependency of Intranasal Oxytocin Effects on Amygdala Reactivity. *Biol Psychiat* 2017; **82**(12): 885-
590 894.
- 591 52. Lan CM, Liu CC, Li KS, Zhao ZY, Yang JX, Ma YN *et al.* Oxytocinergic Modulation of Stress-
592 Associated Amygdala-Hippocampus Pathways in Humans Is Mediated by Serotonergic Mechanisms. *Int*
593 *J Neuropsychoph* 2022; **25**(10): 807-817.
- 594 53. Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person
595 matter. *Trends in Cognitive Sciences* 2011; **15**(7): 301-309.
- 596 54. Andari E, Duhamel J-R, Zalla T, Herbrecht E, Leboyer M, Sirigu A. Promoting social behavior with
597 oxytocin in high-functioning autism spectrum disorders. *Proceedings of the National Academy of*
598 *Sciences* 2010; **107**(9): 4389-4394.
- 599 55. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach
600 to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)* 1995; **57**(1): 289-
601 300.
- 602 56. Esteban O, Markiewicz CJ, Blair RW, Moodie CA, Isik AI, Erramuzpe A *et al.* fMRIprep: a robust
603 preprocessing pipeline for functional MRI. *Nature Methods* 2019; **16**(1): 111-116.
- 604 57. Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations
605 in functional connectivity MRI networks arise from subject motion. *NeuroImage* 2012; **59**(3): 2142-
606 2154.
- 607 58. Motzkin JC, Philippi CL, Wolf RC, Baskaya MK, Koenigs M. Ventromedial Prefrontal Cortex Is
608 Critical for the Regulation of Amygdala Activity in Humans. *Biol Psychiat* 2015; **77**(3): 276-284.
- 609 59. Mihov Y, Kendrick KM, Becker B, Zschernack J, Reich H, Maier W *et al.* Mirroring Fear in the
610 Absence of a Functional Amygdala. *Biol Psychiat* 2013; **73**(7): e9-e11.
- 611 60. Qi S, Hassabis D, Sun J, Guo F, Daw N, Mobbs D. How cognitive and reactive fear circuits optimize
612 escape decisions in humans. *Proceedings of the National Academy of Sciences* 2018; **115**(12): 3186-
613 3191.
- 614 61. Yekutieli D, Benjamini Y. Resampling-based false discovery rate controlling multiple test
615 procedures for correlated test statistics. *Journal of Statistical Planning and Inference* 1999; **82**(1): 171-
616 196.
- 617 62. McLaren DG, Ries ML, Xu G, Johnson SC. A generalized form of context-dependent
618 psychophysiological interactions (gPPI): A comparison to standard approaches. *NeuroImage* 2012;
619 **61**(4): 1277-1286.
- 620 63. Fung BJ, Qi S, Hassabis D, Daw N, Mobbs D. Slow escape decisions are swayed by trait anxiety.
621 *Nature Human Behaviour* 2019; **3**(7): 702-708.
- 622 64. Xu T, Zhou X, Kanen JW, Wang L, Li J, Chen Z *et al.* Angiotensin blockade enhances motivational
623 reward learning via enhancing striatal prediction error signaling and frontostriatal communication.
624 *Molecular Psychiatry* 2023; **28**(4): 1692-1702.
- 625 65. Xin F, Zhou F, Zhou X, Ma X, Geng Y, Zhao W *et al.* Oxytocin Modulates the Intrinsic Dynamics
626 Between Attention-Related Large-Scale Networks. *Cerebral Cortex* 2021; **31**(3): 1848-1860.
- 627 66. Brodmann K, Gruber O, Goya-Maldonado R. Intranasal Oxytocin Selectively Modulates Large-
628 Scale Brain Networks in Humans. *Brain Connectivity* 2017; **7**(7): 454-463.
- 629 67. Ruslan M, Irina K, Alexander K, Denis C, Maxim K. Comparison of whole-brain task-modulated
630 functional connectivity methods for fMRI task connectomics. *bioRxiv* 2024: 2024.2001.2022.576622.
- 631 68. Schmäzle R, Brook O'Donnell M, Garcia JO, Cascio CN, Bayer J, Bassett DS *et al.* Brain
632 connectivity dynamics during social interaction reflect social network structure. *Proceedings of the*
633 *National Academy of Sciences* 2017; **114**(20): 5153-5158.
- 634 69. Foster Brett L, Rangarajan V, Shirer William R, Parvizi J. Intrinsic and Task-Dependent Coupling of
635 Neuronal Population Activity in Human Parietal Cortex. *Neuron* 2015; **86**(2): 578-590.

- 636 70. Giordano BL, Whiting C, Kriegeskorte N, Kotz SA, Gross J, Belin P. The representational dynamics
637 of perceived voice emotions evolve from categories to dimensions. *Nature Human Behaviour* 2021;
638 **5**(9): 1203-1213.
- 639 71. Cole MW, Reynolds JR, Power JD, Repovs G, Anticevic A, Braver TS. Multi-task connectivity reveals
640 flexible hubs for adaptive task control. *Nat Neurosci* 2013; **16**(9): 1348-1355.
- 641 72. Uddin LQ. Cognitive and behavioural flexibility: neural mechanisms and clinical considerations.
642 *Nature Reviews Neuroscience* 2021; **22**(3): 167-179.
- 643 73. Simony E, Honey CJ, Chen J, Lositsky O, Yeshurun Y, Wiesel A *et al.* Dynamic reconfiguration of the
644 default mode network during narrative comprehension. *Nature Communications* 2016; **7**(1): 12141.
- 645 74. Axelrod V, Rees G, Bar M. The default network and the combination of cognitive processes that
646 mediate self-generated thought. *Nature Human Behaviour* 2017; **1**(12): 896-910.
- 647 75. Peter K, Christine E, Qiang C, Daniela M, Stefanie L, Sarina S *et al.* Oxytocin Modulates Neural
648 Circuitry for Social Cognition and Fear in Humans. *The Journal of Neuroscience* 2005; **25**(49): 11489.
- 649 76. Sonkusare S, Breakspear M, Guo C. Naturalistic Stimuli in Neuroscience: Critically Acclaimed.
650 *Trends in Cognitive Sciences* 2019; **23**(8): 699-714.
- 651 77. Menon R, Neumann ID. Detection, processing and reinforcement of social cues: regulation by the
652 oxytocin system. *Nature Reviews Neuroscience* 2023; **24**(12): 761-777.
- 653 78. Xu X, Li J, Chen Z, Kendrick KM, Becker B. Oxytocin reduces top-down control of attention by
654 increasing bottom-up attention allocation to social but not non-social stimuli – A randomized
655 controlled trial. *Psychoneuroendocrinology* 2019; **108**: 62-69.
- 656 79. Mobbs D, Trimmer PC, Blumstein DT, Dayan P. Foraging for foundations in decision neuroscience:
657 insights from ethology. *Nature Reviews Neuroscience* 2018; **19**(7): 419-427.
- 658 80. Tashjian SM, Zbozinek TD, Mobbs D. A Decision Architecture for Safety Computations. *Trends in*
659 *Cognitive Sciences* 2021; **25**(5): 342-354.
- 660 81. van Heukelum S, Mars RB, Guthrie M, Buitelaar JK, Beckmann CF, Tiesinga PHE *et al.* Where is
661 Cingulate Cortex? A Cross-Species View. *Trends in Neurosciences* 2020; **43**(5): 285-299.
- 662 82. Loh KK, Procyk E, Neveu R, Lambertson F, Hopkins WD, Petrides M *et al.* Cognitive control of
663 orofacial motor and vocal responses in the ventrolateral and dorsomedial human frontal cortex.
664 *Proceedings of the National Academy of Sciences* 2020; **117**(9): 4994-5005.
- 665 83. Shackman AJ, Salomons TV, Slagter HA, Fox AS, Winter JJ, Davidson RJ. The integration of
666 negative affect, pain and cognitive control in the cingulate cortex. *Nature Reviews Neuroscience* 2011;
667 **12**(3): 154-167.
- 668 84. Koch SBJ, van Zuiden M, Nawijn L, Frijling JL, Veltman DJ, Olf M. Intranasal Oxytocin Normalizes
669 Amygdala Functional Connectivity in Posttraumatic Stress Disorder. *Neuropsychopharmacology* 2016;
670 **41**(8): 2041-2051.
- 671 85. Patel GH, Yang D, Jamerson EC, Snyder LH, Corbetta M, Ferrera VP. Functional evolution of new
672 and expanded attention networks in humans. *Proceedings of the National Academy of Sciences* 2015;
673 **112**(30): 9454-9459.
- 674 86. Womelsdorf T, Everling S. Long-Range Attention Networks: Circuit Motifs Underlying
675 Endogenously Controlled Stimulus Selection. *Trends in Neurosciences* 2015; **38**(11): 682-700.
- 676 87. Rosenberg MD, Finn ES, Scheinost D, Constable RT, Chun MM. Characterizing Attention with
677 Predictive Network Models. *Trends in Cognitive Sciences* 2017; **21**(4): 290-302.
- 678 88. Dixon ML, De La Vega A, Mills C, Andrews-Hanna J, Spreng RN, Cole MW *et al.* Heterogeneity
679 within the frontoparietal control network and its relationship to the default and dorsal attention
680 networks. *Proceedings of the National Academy of Sciences* 2018; **115**(7): E1598-E1607.
- 681 89. Keller AS, Sydnor VJ, Pines A, Fair DA, Bassett DS, Satterthwaite TD. Hierarchical functional system
682 development supports executive function. *Trends in Cognitive Sciences* 2023; **27**(2): 160-174.
- 683 90. Satpute AB, Lindquist KA. The Default Mode Network's Role in Discrete Emotion. *Trends*
684 *in Cognitive Sciences* 2019; **23**(10): 851-864.
- 685 91. Sylvester CM, Corbetta M, Raichle ME, Rodebaugh TL, Schlaggar BL, Sheline YI *et al.* Functional
686 network dysfunction in anxiety and anxiety disorders. *Trends in Neurosciences* 2012; **35**(9): 527-535.
- 687 92. Xu S, Zhang Z, Li L, Zhou Y, Lin D, Zhang M *et al.* Functional connectivity profiles of the default
688 mode and visual networks reflect temporal accumulative effects of sustained naturalistic emotional
689 experience. *NeuroImage* 2023; **269**: 119941.
- 690 93. Brandman T, Malach R, Simony E. The surprising role of the default mode network in naturalistic
691 perception. *Communications Biology* 2021; **4**(1): 79.

- 692 94. Davies C, Martins D, Dipasquale O, McCutcheon RA, De Micheli A, Ramella-Cravarro V *et al.*
693 Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin.
694 *Molecular Psychiatry* 2024.
- 695 95. Chai Y, Sheline YI, Oathes DJ, Balderston NL, Rao H, Yu M. Functional connectomics in depression:
696 insights into therapies. *Trends in Cognitive Sciences* 2023; **27**(9): 814-832.
- 697 96. Yan C-G, Chen X, Li L, Castellanos FX, Bai T-J, Bo Q-J *et al.* Reduced default mode network
698 functional connectivity in patients with recurrent major depressive disorder. *Proceedings of the*
699 *National Academy of Sciences* 2019; **116**(18): 9078-9083.
- 700 97. Liu X, Jiao G, Zhou F, Kendrick KM, Yao D, Gong Q *et al.* A neural signature for the subjective
701 experience of threat anticipation under uncertainty. *Nature Communications* 2024; **15**(1): 1544.
- 702 98. Zhang H, Chen K, Bao J, Wu H. Oxytocin enhances the triangular association among behavior,
703 resting-state, and task-state functional connectivity. *Human Brain Mapping* 2023; **44**(17): 6074-6089.
- 704 99. Quintana DS, Rokicki J, van der Meer D, Alnæs D, Kaufmann T, Córdova-Palomera A *et al.*
705 Oxytocin pathway gene networks in the human brain. *Nature Communications* 2019; **10**(1): 668.
- 706 100. Deco G, Kringelbach Morten L. Great Expectations: Using Whole-Brain Computational
707 Connectomics for Understanding Neuropsychiatric Disorders. *Neuron* 2014; **84**(5): 892-905.
- 708
709